Sutent Maintenance After Response to Taxotere
NCT00550810
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Prostate Cancer
Hormone Refractory
Interventions
DRUG:
Sunitinib (SU011248)
Sponsor
Alberta Health services
Collaborators
[object Object]